Viking Therapeutic (VKTX) Positive Early Data in X-ALD Adds New Future Catalyst - Raymond James

June 17, 2021 11:07 AM EDT
Get Alerts VKTX Hot Sheet
Price: $6.54 +1.55%

Rating Summary:
    13 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 13 | New: 52
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Raymond James analyst Steve Seedhouse reiterated an Outperform rating and $12.00 price target on Viking Therapeutic (NASDAQ: VKTX) after the company reported topline data from a Phase 1 study evaluating oral thyroid hormone receptor beta (THR-β) agonist, VK0214.

VK0214 treatment resulted in statistically significant reductions in LDL cholesterol, triglycerides, and Apolipoprotein B (ApoB) after 14-days, beginning at doses as low as 10mg (dosing range: 5-100mg).

"In short, the Phase 1a data suggest the mechanism is potentially active in X-ALD, but X-ALD patient data will be a much more informative and useful indicator of efficacy, thus adding a new and interesting catalyst to Viking's otherwise NASH-focused calendar which is the bigger takeaway," the analyst commented.

For an analyst ratings summary and ratings history on Viking Therapeutic click here. For more ratings news on Viking Therapeutic click here.

Shares of Viking Therapeutic closed at $6.08 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Raymond James